GLUE
Monte RosaยทNASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
GLUE Profile
Monte Rosa Therapeutics, Inc.
A biotech company that develops novel molecular glue degrader (MGD)-based medicines
321 Harrison Avenue, Suite 900, Boston, Massachusetts, 02118
--
Monte Rosa Therapeutics, Inc., was incorporated in Delaware in November 2019. The company is a biopharmaceutical company that develops a range of new small molecule precision medicines that use the body's natural mechanisms to selectively degrade treatment-related proteins. The company has developed a proprietary protein degradation platform called QuEEN, which is capable of rapidly identifying protein targets and molecular gel degraders (MGDs), product candidates designed to eliminate therapeutically relevant proteins in a highly selective manner. The company believes that the small molecule MGD may have significant advantages over existing treatments because the company allows the targeting of proteins that are considered undruggable or undermedicated. The company focuses on therapeutic goals backed by strong biological and genetic principles, with the goal of discovering and developing new precision medicines. These opportunities include oncology and non-oncology indications, including immunology, inflammation, neurological and genetic diseases.
